Search results
Found 22471 matches for
Baricitinib – an anti-inflammatory treatment for rheumatoid arthritis– is being investigated in the RECOVERY trial, the world’s largest clinical trial of treatments for patients hospitalised with COVID-19, taking place in 177 hospital sites across the UK and with over 33,000 patients recruited so far. As an anti-inflammatory, baricitinib may block the signalling activity of cytokine molecules which contribute to the hyper-inflammatory state seen in severe COVID-19. It is thought that baricitinib may act also have some anti-viral activity. The other treatments currently being investigated in the RECOVERY trial are Regeneron’s antibody cocktail, Aspirin and Colchicine.
Peter Horby
FRS Peter Horby - Moh Family Foundation Professor of Emerging Infections and Global Health
Louise Thwaites
BSc MBBS MRCP MD DMSMed MLCOM Louise Thwaites - Professor of Experimental Critical Care
Brian Angus
BSc, MBChB, DTM&H, FRCP, MD, FFTM Brian Angus - Professor of Practice, Medical Education and Reader in Infectious Diseases
Proochista Ariana
- MSc IHTM Lecturers
- MSc IHTM advisory committee
- MSc IHTM steering committee
- MSc MGH Lecturers
- Principal Investigators
- Research Scientists
Proochista Ariana - Associate Professor
David Warrell
DM, DSc, FRCP, FRCPE, FMedSci; HonF CeylonCP, RThaiCP, WestAfrCP, CPSMumbai David Warrell - Emeritus Professor of Tropical Medicine